1016eTiP A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress)

作者：S. Kitano, A. Patnaik, V. Subbiah, Takahiko Koyama, Apurvasena Parikh, R. Yaeger, Benjamin Herzberg, Rachel Galot, Ju Hee Lee, E. Garralda, Davide Melisi, T.O. Goetze, Philippe A. Cassier, Li J, Matthew P. Hanley, Jennifer Wright, A. Bence Lin, M. Axelson, Nehal J. Lakhani · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.08.1585 · 被引用次数：3 · 研究领域：Protein Kinase Regulation and GTPase Signaling、HER2/EGFR in Cancer Research、Colorectal Cancer Treatments and Studies